Literature DB >> 10349691

Standards of treatment in chronic hepatitis C.

R G Gish1.   

Abstract

Standards of treatment for patients who are infected with the hepatitis C virus have been developed from national and international consensus conferences, from extensive clinical experience with various regimens, from exhaustive literature reviews, and from opinion leaders in the general medical community. From 1987 until very recently, the standard of treatment for non-A, non-B hepatitis, later defined as hepatitis C, had consisted of alpha interferon monotherapy administered for up to 18 to 24 months. Alpha interferon has been used in a variety of regimens with varying success for the initial treatment of chronic hepatitis C, for the retreatment of patients who have relapsed after responding to interferon, and for the retreatment of alpha interferon nonresponders. Treatment standards have evolved as new agents have become available for use in our treatment armamentarium. The current treatment standards, as well as recommendations for the treatment of specific HCV subgroups, are reviewed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10349691

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  10 in total

Review 1.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

Review 2.  Treatment of chronic hepatitis C in nonresponders to interferon monotherapy.

Authors:  P Y Kwo
Journal:  Curr Gastroenterol Rep       Date:  2000-02

3.  Current Views on Hepatitis C Virus Infection.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-02       Impact factor: 3.725

4.  Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit assay and the National Genetics Institute HCV Superquant assay.

Authors:  Eric Q Konnick; Maria Erali; Edward R Ashwood; David R Hillyard
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

5.  Hepatitis C virus infection in young, low-income women: the role of sexually transmitted infection as a potential cofactor for HCV infection.

Authors:  Kimberly A Page-Shafer; Barbara Cahoon-Young; Jeffrey D Klausner; Scott Morrow; Fred Molitor; Juan Ruiz; Willi McFarland
Journal:  Am J Public Health       Date:  2002-04       Impact factor: 9.308

6.  Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.

Authors:  Zobair M Younossi; Arthur C McCullough; David S Barnes; Anthony Post; Janus P Ong; Robert O'Shea; Lisa M Martin; Diane Bringman; Denise Farmer; Gavin Levinthal; Kevin D Mullen; William D Carey; Anthony S Tavill; Roy Ferguson; Terry Gramlich
Journal:  Dig Dis Sci       Date:  2005-05       Impact factor: 3.199

7.  Interferons activate the p42/44 mitogen-activated protein kinase and JAK-STAT (Janus kinase-signal transducer and activator transcription factor) signalling pathways in hepatocytes: differential regulation by acute ethanol via a protein kinase C-dependent mechanism.

Authors:  V A Nguyen; J Chen; F Hong; E J Ishac; B Gao
Journal:  Biochem J       Date:  2000-07-15       Impact factor: 3.857

8.  Effect of interferon and ribavirin combined with amantadine in interferon and ribavirin non-responder patients with chronic hepatitis C (genotype 1).

Authors:  Dilek Oguz; Bahattin Cicek; Levent Filik; Bulent Odemis; Mesut Kilic; Engin Altintas; Neslihan Zengin; Emin Altiparmak
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

9.  Alanine aminotransferase flare-up in hepatitis C virus carriers with persistently normal alanine aminotransferase levels in a hyperendemic area of Japan.

Authors:  Hirofumi Uto; Joji Kurogi; Yuka Takahama; Kazunori Kusumoto; Katsuhiro Hayashi; Akio Ido; Michinori Kohara; Sherri O Stuver; Akihiro Moriuchi; Susumu Hasegawa; Makoto Oketani; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2007-08-24       Impact factor: 7.527

10.  Hepatitis C.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.